Characteristics and Outcomes of Fast Progressors Receiving Endovascular Treatment for Acute Large Vessel Occlusion: A

Mingming Zha1, Shuaiyu Chen2, Jinhua Wang1

  • 1Department of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Insights

Fast progressors in acute large vessel occlusion strokes show higher severity, worse collaterals, and cardioembolic causes. These patients face worse outcomes after endovascular treatment (EVT), highlighting the need to consider infarction growth rate (IGR) in stroke management.

Area of Science:

  • Neurology
  • Interventional Neuroradiology
  • Stroke Medicine

Background:

  • Acute large vessel occlusion (LVO) stroke patients are categorized by infarction growth rate (IGR) into fast and slow progressors before endovascular treatment (EVT).
  • Characteristics of fast progressors and the adverse effects of rapid infarction growth remain incompletely understood.

Purpose of the Study:

  • To comprehensively review and characterize fast progressors in acute LVO stroke.
  • To investigate the clinical outcomes associated with rapid infarction growth rate before EVT.

Main Methods:

  • Systematic literature search of studies comparing fast and slow progressors before EVT, published up to March 24, 2025.
  • Meta-analysis of baseline characteristics and clinical outcomes from 8 pooled studies involving 2,718 patients.
  • Calculation of weighted odds ratios (OR) and mean differences (MD) with confidence intervals (CIs).

Main Results:

  • Fast progressors exhibited higher NIH Stroke Scale scores, increased rates of intravenous thrombolysis, more internal carotid artery occlusions, and poorer collateral status.
  • Cardioembolism was a prevalent etiology in fast progressors.
  • Fast IGR was linked to lower successful reperfusion rates, reduced good functional outcomes (mRS 0-2), and higher rates of symptomatic intracranial hemorrhage and 90-day mRS scores.

Conclusions:

  • Key features of fast progressors include stroke severity, proximal occlusion, poor collaterals, and cardioembolic etiology.
  • Fast progressors face significantly increased risks of adverse outcomes following EVT.
  • Incorporating IGR assessment into clinical practice and research is crucial for optimizing stroke management.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
26
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
29
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
33
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
259